Correction: Wells Fargo Maintains Overweight on Editas Medicine, Lowers Price Target to $9. (Rating changed)
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Yanan Zhu maintains an Overweight rating on Editas Medicine but lowers the price target from $27 to $9.
October 23, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo has maintained its Overweight rating on Editas Medicine but significantly reduced the price target from $27 to $9, indicating a more cautious outlook.
The reduction in the price target from $27 to $9 by Wells Fargo suggests a significant decrease in expected future performance for Editas Medicine. This could lead to a negative short-term impact on the stock price as investors may reassess their positions based on the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100